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Short communication
Lack of interleukin 6 (IL-6) and transforming growth
factor a (TGF-a) expression in chromophobe renal cell
carcinomas
J Chudek, D Schullerus, M Wilhelm and G Kovacs
Laboratory of Molecular Oncology. Department of Urology. Ruprecht-Karls-University. Heidelberg, Im Neuenheimer Feld 365. D-69120 Heidelberg. Germany
Summary We demonstrate the constitutive expression of interleukin 6 (IL-6), IL-8. granulocyte-macrophage colony-stimulating factor (GM-
CSF), epidermal growth factor (EGF), transforming growth factor alpha (TGF-a) and epidermal growth tactor receptor (EGFR) in normal
kidney cells, and in the majority of renal oncocytomas, papillary and non-papillary renal cell carcinomas (RCCs) by reverse transcnptase
polymerase chain reaction (RT-PCR) technique. No expression of IL-6 and TGF-a and variable expression of GM-CSF. IL-8, EGF and EGFR
was seen in chromophobe RCCs. The lack ofexpression ofIL-6 and TGF-a mightbe correlated with thegrowth pattem. poorvascularityand
low malignancy ofchromophobe RCCs.
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Normal renal parenchymal cells as %vell as renal cell carcinomas
(RCCs) can produce constitutivels different cytokines. grow-th
factors and their receptors. which might be involved in tumour cell
proliferation via the autocrine loop. An enhanced expression of
interleukin 6 (IL-6) has been associated xiith the arowth. invasixe-
ness and chemoresistance of RCCs and with inflammatorv
response (Miki et al. 1989: Koo et al. 1992: Gogusev et al. 1993).
The constitutive expression of IL-8 and granulocyte-macrophage
colonv-stimulating factor (GGM-CSF) was shown in the majoritx of
RCCs (Stephens et al. 1996). The increased number of epidermal
growth factor (EGF)-receptor molecules and enhanced expression
of its liands EGF and transformingc,groth factor alpha (TGFa)
in RCCs suggest that these genes are insolhed in the growth
regulation via autocrine loop (Atlas et al. 1992: Lager et al. 1994:
AoNagi et al. 1996). All these studies were camed out on RCCs in
Ceneral. Recent cenetic studies. however. uncovered highl-
specific alterations marking distinct types of renal tumours and
resulted in a new classification system (Kovacs et al. 1997). The
aim of this studsx was to establish the expression profile of the
aboxe-mentioned genes in the four major genetic subtypes ofrenal
cell tumours (RCe) bx the reverse transcriptase polvmerase chain
reaction (RT-PCR) technique.
MATERIAL AND METHODS
Tumour samples and cell culture
Fresh normal and tumour tissues were obtained from the
Departments of Urology at the Medical School Hannover and at
the Unixersitx of Heidelberg. All tumours wxere diagnosed
according to the Heidelberg Classification system (Kovacs et al.
1997). and were analysed for pathognomonic 2enetic alterations
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bv a microsatellite assay (Bugert et al. 1997: Palmedo et al. 1997:
Schullerus et al. 1997: Herbers et al. 1998). Because tumour
tissues of most RCTs contain cvtokine-producing granulocvtes.
monocy-tes and macrophages. wxe anaIx-sed tumour cells gfrowinza
in primarv culture or in the first passage. Cell cultures w-ere
prepared by a combined enzymatic-mechanical technique
described earlier (Bugert and Koxacs. 1996). Cells w-ere rrow-n in
RPMI-1640 medium (Gibco). supplemented with 10%1e fetal calf
serum. No antibiotics or antimx cotics w-ere added.
RT-PCR analysis
Total RNA was isolated from near confluent primanr cultures w-ith
Trisol LS reagent (Life Technologies. Bethesda. MD. USA). Five
micrograms of RNA were reverse transcribed w-ith 70 pmol olinlo-
dT, primer and 200 U Superscript II (Life Technologies) in a 40-il
Volume for 1 h at 42 C. RNA was degraded bx alkali treatment. and
the cDNA was neutralized, ethanol precipitated and resuspended in
20pl water. One microlitre was then amplified xxith appropriate
primers: IL-6 sense primer5'-TATCTCCCCTCCAGGAGCCCAG-
3': IL-6 antisense primer 5'-CATCCATUCI'1'TFITCAGCC-3': IL-8
sense primer 5'-GC(TCTAGGACAAGAGCCAGGAAG-3': IL-8
antisense primer5'-CT7GGATACCACAGAGAATGAATlI-t':
GM-CSF sense primer 5'-ATGTGGCTGCAGAGCCTGCTGC-3':
GM-CSF antisense primer 5'-TCCAGCCTCATCGGCCGGT-3':
TGFa sense primer5'-TGTTCGCTCTGGGTATTG-3': TGFa anti-
sense primer 5'-TGATGATAAGGACAGCCA-3': EGF sense
pnmer 5'-GACGCCTGTCTGAACCAGGA-3': EGF antisense
pnmer 5'-CGATAGCAGCTTCTGAGGGTCC-3': EGFR sense
pnmer 5'-GGGT7F1-fl-GCTGATTFCAGGC-3': EGFR antisense
primer 5'-CCAGGGTGTTGTTTl'CTCCC-3'. DNA amphification
>-as carried out wxith the pimers mentioned aboxe in 96-well polv-
carbonate plates using a PFC 200 thermocycler (MJ Research). The
PCR was performed in 20 pl reaction xolume containing of 1 ll of
cDNA. 50 nvsm potassium chloride. 10 mmt Tris (pH 7.0). 1.5 nIsm
magnesium chloride. 200 nm dNTP. 10pmol of each primer and
0.5 U of Taq polymerase. The ,B3-microglobulin gene w-as used as a
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positive control and was amplified using the sense pnrmer 5'-CFCG-
CGCTACTCTCTCTlTCCT-3' and antisense primer 5'-TGTCGGA-
TTGATGAAACCCAG-3'. DNA fragments were amplified by 40
cycles with denaturing for 30 s at 94zC. annealine for 60 s at 58-C
and extension for 60 s at 72'C. The PCR products were electro-
phoresed on a 2g% agarose gel and stained with ethidium bromide.
RESULTS AND DISCUSSION
A panel of five normal kidney samples. six chromophobe. ten
papillarn and ten non-papillar- RCCs. and ten renal oncocytomas
were analysed for expression of IL-6. IL-8 and GM-CSF. as u-ell
as for EGFR and its ligands. Most tumours, with exception of
chromophobe RCC. showed expression of all genes analy-sed
(Table 1). The expression pattern of IL-6 and IL-8 is shown in
Figure 1. As we hase analysed pure tumour cell populations. our
study indicates that these cenes are expressed by the tumour cells
themselves.
We have compared the expression profile and aHlelic alterations
determined earlier at loci of each gene in tumour types (Bugert et
al. 1997: Herbers et al. 1997: Palmedo et al. 1997: Schullerus et al.
1997). TGFax is localized on chromosome 2pI3. GM-CSF on
chromosome 5q31. IL-6 and EGFR on chromosome 7p. and EGF
and IL-8 are on chromosome 4. Our data suggest that expression
of IL-6. IL-8. GM-CSF. TGFa. EGF and EGFR in RCTs. with the
exception ofTGFa in chromophobe RCCs. does not correlate w-ith
genomic copy number in the tumour cells. Probably. these genes
are expressed ubiquitouslN in all but one type of RCT. We also
could not confirm the result of a recent studv showing an associa-
tion between high secretion of GM-CSF and trisomy of chromo-
some Sq (Lahn et al. 1997).
Interleukin 6. TGFt and GM-CSF induce angiogenesis via
induction of vascular endothelial growth factor (VEGF) mRNA
expression (Sunderkotter et al. 1994: Cohen et al. 1996).
Chromophobe RCCs are poorly s-asculanrzed and ggrow in large
solid sheets ofepithehal cells. This is in contrast to other types of
Table 1 Gene expression in distinct types of renal cell tumours
Genes, their loci and number of cases with expression
Samples IL-6 IL-8 GM-CSF EGFR EGF TGFa
(no. cases) 7p14-21 4q12-21 5q31 7p21 4q25 2p13
Normal (5) 5 5 5 5 5 5
chRCCa (6) 0 4 1 4 3 0
pRCT (10) 8 10 9 10 5 7
npRCC (10) 9 10 4 9 6 8
RO (10) 6 8 8 10 6 6
achRCC. chromophobe renal cell carcinomas: pRCT. papillary renal cell tumours: npRCC. non-papillary
renal cell carcinomas: RO. renal oncocytoma.
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Figure 1 RT-PCR anatysis of e IL-6 and IL-8 in normal kidney cells (1-5) chromophobe RCCs (-11), papillary RCTs (12-21). non-papillary RCCs (22-31)
and renal oncocytomas (32-41). The size of PCR products in base pairs: IL-6 (326), IL-8 (389) and 52 microglobulin (137). Notce the lack of IL-6 expression in
chromophobe RCCs. Marker bands A and B correspond to sizes of 506 and 220 bp respectivety
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renal cell tumours, which are rich in vascular stroma. Although
chromophobe RCCs show high mitotic activity and DNA aneu-
ploidy, more than 90% of the patients are alive 5 years after
nephrectomy indicating a low progression rate of this type of
tumour (Akhtar et al, 1995; Crotty et al, 1995). It is probable that
lack of, or reduced expression of, LL-6, TGFa and GM-CSF is
responsible for the poor tumour angiogenesis and, consequently.
for the unique growth pattem and low malignancy of chromo-
phobe RCCs.
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